An eventual approval for this indication if received will significantly expand the addressable patient population with approximately 30% of the U.S. population reported to suffer from motion sickness under ordinary travel conditions that include sea, air, and land.

May 8, 2024 / CEO / receipt, needs a key / Dr. Mahalis Polymeropoulos, CEO | earnings call 2024-05-08 | transcript 07145980-0a1b-4190-94a8-cea816def0d6 | chars 11135-11400 | segment 10